Skip to Content
Merck
  • Novel drug combination for Mycobacterium abscessus disease therapy identified in a Drosophila infection model.

Novel drug combination for Mycobacterium abscessus disease therapy identified in a Drosophila infection model.

The Journal of antimicrobial chemotherapy (2014-02-13)
Chun-Taek Oh, Cheol Moon, Ok Kyu Park, Seung-Hae Kwon, Jichan Jang
ABSTRACT

Mycobacterium abscessus is known to be the most drug-resistant Mycobacterium and accounts for ∼80% of pulmonary infections caused by rapidly growing mycobacteria. This study reports a new Drosophila melanogaster-M. abscessus infection model that can be used as an in vivo efficacy model for anti-M. abscessus drug potency assessment. D. melanogaster were challenged with M. abscessus, and infected flies were fed with a fly medium containing tigecycline, clarithromycin, linezolid, clofazimine, moxifloxacin, amikacin, cefoxitin, dinitrobenzamide or metronidazole at different concentrations (0, 100 and 500 mg/L). The survival rates of infected flies were plotted and bacterial colonization/dissemination in fly bodies was monitored by cfu determination and green fluorescent protein epifluorescence. The D. melanogaster-M. abscessus model enabled an assessment of the effectiveness of antibiotic treatment. Tigecycline was the best drug for extending the lifespan of M. abscessus-infected Drosophila, followed by clarithromycin and linezolid. Several different combinations of tigecycline, linezolid and clarithromycin were tested to determine the best combination. Tigecycline (25 mg/L) plus linezolid (500 mg/L) was the best drug combination and its efficacy was superior to conventional regimens, not only in prolonging infected fly survival but also against M. abscessus colonization and dissemination. This D. melanogaster-M. abscessus infection/curing methodology may be useful for the rapid evaluation of potential drug candidates. In addition, new combinations using tigecycline and linezolid should be considered as possible next-generation combination therapies to be assessed in higher organisms.

MATERIALS
Product Number
Brand
Product Description

Supelco
Metronidazole, VETRANAL®, analytical standard
Sigma-Aldrich
D-Glucose-12C6, 16O6, 99.9 atom % 16O, 99.9 atom % 12C
Supelco
D-(+)-Glucose, analytical standard
Sigma-Aldrich
D-(+)-Glucose, tested according to Ph. Eur.
Sigma-Aldrich
D-(+)-Glucose, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99.5%
Sigma-Aldrich
D-(+)-Glucose, ≥99.5% (GC)
Sigma-Aldrich
D-(+)-Glucose, suitable for mouse embryo cell culture, ≥99.5% (GC)
Sigma-Aldrich
D-(+)-Glucose, ≥99.5% (GC), BioXtra
Sigma-Aldrich
D-(+)-Glucose, Hybri-Max, powder, BioReagent, suitable for hybridoma
Sigma-Aldrich
D-(+)-Glucose, ACS reagent
Supelco
Metronidazole, analytical standard
Sigma-Aldrich
Metronidazole, BioXtra
Supelco
Cefoxitin sodium salt
Sigma-Aldrich
Linezolid, ≥98% (HPLC)
Sigma-Aldrich
Clarithromycin, 96.0-102.0% (HPLC)
Clarithromycin for peak identification, European Pharmacopoeia (EP) Reference Standard
Clarithromycin, European Pharmacopoeia (EP) Reference Standard
USP
Clarithromycin, United States Pharmacopeia (USP) Reference Standard
Cefoxitin sodium, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Clarithromycin, ≥95% (HPLC)
Supelco
Clarithromycin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Metronidazole, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
D-(+)-Glucose, BioUltra, anhydrous, ≥99.5% (sum of enantiomers, HPLC)
Cefoxitin sodium for peak identification, European Pharmacopoeia (EP) Reference Standard
Metronidazole, European Pharmacopoeia (EP) Reference Standard
Supelco
Dextrose, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Oleic acid, Selectophore, ≥99%
Sigma-Aldrich
Tigecycline hydrate, ≥98% (HPLC)
USP
Clarithromycin Identity, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Oleic acid, technical grade, 90%